a Slovak Academy of Sciences , Institute of Chemistry , Bratislava , Slovakia.
b Glycanostics Ltd ., Bratislava , Slovakia.
Expert Rev Proteomics. 2019 Jan;16(1):65-76. doi: 10.1080/14789450.2019.1549993. Epub 2018 Nov 27.
: Prostate cancer (PCa) is a life-threatening disease affecting millions of men. The current best PCa biomarker (level of prostate-specific antigen in serum) lacks specificity for PCa diagnostics and this is why novel PCa biomarkers in addition to the conventional ones based on biomolecules such as DNA, RNA and proteins need to be identified. : This review details the potential of glycans-based biomarkers to become diagnostic, prognostic, predictive and therapeutic PCa biomarkers with a brief description of the innovative approaches applied to glycan analysis to date. Finally, the review covers the possibility to use exosomes as a rich source of glycans for future innovative and advanced diagnostics of PCa. The review covers updates in the field since 2016. : The summary provided in this review paper suggests that glycan-based biomarkers can offer high-assay accuracy not only for diagnostic purposes but also for monitoring/surveillance of the PCa disease.
前列腺癌（PCa）是一种危及生命的疾病，影响着数以百万计的男性。目前用于前列腺癌诊断的最佳生物标志物（血清前列腺特异性抗原水平）特异性不足，因此需要确定新的前列腺癌生物标志物，除了基于 DNA、RNA 和蛋白质等生物分子的传统生物标志物之外。本文详细介绍了基于聚糖的生物标志物在诊断、预后、预测和治疗前列腺癌方面的潜力，并简要描述了迄今为止应用于聚糖分析的创新方法。最后，本文还探讨了利用外泌体作为未来前列腺癌创新和先进诊断的丰富聚糖来源的可能性。本文综述了自 2016 年以来该领域的最新进展。本文综述表明，基于聚糖的生物标志物不仅可以提供高分析准确性，而且可以用于诊断目的，还可以用于监测/随访前列腺癌疾病。
